New to peptides? Start with the foundations ->
The dad-test answer
These hit different receptors. Tesamorelin is a GHRH analog with FDA approval for HIV lipodystrophy and the strongest VAT-reduction evidence in the GH-axis category. Ipamorelin is a selective ghrelin-receptor agonist with the cleanest side-effect profile of any GH peptide - no cortisol or prolactin spike. Many operators run them together because GHRH + ghrelin agonist produces a larger GH pulse than either alone. Tesamorelin for clinical VAT; ipamorelin for daily GH-axis support.
Who wins for what
| Use case | Who wins, and why |
|---|---|
| visceral adipose tissue (VAT) reduction |
tesamorelin Phase 3 trials (Falutz et al., NEJM 2007) showed about 15% VAT reduction at 26 weeks via GHRH-receptor activation. |
| side-effect cleanliness, no cortisol spike |
ipamorelin Raun 1998 established ipamorelin doesn't raise cortisol, prolactin, or ACTH - cleanest GH secretagogue available. |
| FDA approval and insurance path |
tesamorelin Egrifta and Egrifta SV are FDA-approved for HIV lipodystrophy; ipamorelin has never been FDA-reviewed in humans. |
| stack synergy |
tie - run both GHRH + ghrelin-receptor agonist hits two receptors and produces a larger combined GH pulse than either alone. |
What the head-to-head data shows
These two peptides hit different receptors and the case for stacking them is real, similar to the CJC-1295 + ipamorelin pairing. Tesamorelin is a synthetic GHRH analog FDA-approved as Egrifta in 2010 for excess abdominal fat in HIV-related lipodystrophy. Falutz et al., NEJM 2007 is the pivotal Phase 3 - 412 HIV patients with central fat accumulation, daily 2mg subQ tesamorelin for 26 weeks reduced visceral adipose tissue by about 15-18% with 69% of patients achieving clinically meaningful reduction. Ipamorelin is a synthetic pentapeptide selective for the growth hormone secretagogue receptor (ghrelin receptor); Raun et al. 1998 characterized its selectivity - no elevation in cortisol, prolactin, or ACTH, unlike older GHRPs. Ipamorelin reached Phase 2b for postoperative ileus before development was discontinued; it's research-use-only without FDA approval. The receptor-pairing logic is the same as CJC-1295 + ipamorelin: GHRH-receptor agonism plus ghrelin-receptor agonism produces a synergistic GH pulse.
Our honest call
If a reader has a clinical indication for VAT reduction - HIV-lipodystrophy, or stubborn visceral fat that hasn't responded to GLP-1 therapy or lifestyle work - tesamorelin is the molecule with full FDA-approved Phase 3 evidence. The friction is cost ($4-5K/month retail without insurance) and access. For general GH-axis support (sleep, recovery, body recomp at the margins), ipamorelin solo or stacked with a GHRH analog is the standard biohacker protocol - cheaper, easier to source, with the cleanest side-effect profile in the category. If a reader is building a pulsatile GH-axis stack on tesamorelin instead of CJC-1295, the pairing with ipamorelin makes biological sense - same receptor logic, just trading the research-grade GHRH for the FDA-approved one. Read the tesamorelin VAT protocol for the regulatory side and the CJC-1295 + ipamorelin protocol for the operator stack.
Sources and citations
- Falutz et al., Tesamorelin Phase 3 in HIV lipodystrophy, NEJM 2007 (PMID 18075072)
- FDA Egrifta prescribing label (approved Nov 2010)
- Raun et al., Ipamorelin GH-releasing peptide, Eur J Endocrinol 1998 (PMID 9849822)
- Sigalos and Pastuszak, GH secretagogue review, Sex Med Rev 2018
- Theratechnologies Egrifta SV prescribing information
Where to go next
Subscribe to the dispatch
The weekly Protocol One dispatch covers what's moving in peptides, GLP-1s, and longevity protocols. Free. 5-min read. Broken down for normal humans.
Last reviewed · 2026-05-07 · Page generated by Protocol One matrix engine. None of this replaces a doctor. Peptides are gray-market in the US for most uses. Talk to a real prescriber before you change anything.